UPDATE: JPMorgan Downgrades Protagonist Therapeutics (PTGX) to Neutral
Tweet Send to a Friend
(Updated - September 20, 2021 4:45 AM EDT)
JPMorgan analyst Anupam Rama downgraded Protagonist Therapeutics (NASDAQ: PTGX) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama downgraded Protagonist Therapeutics (NASDAQ: PTGX) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
